Background
DNA methylation is a stable, dominant, and inheritable epigenetic modification that silences genes in somatic cells [
1‐
3]. Through DNA methylation, environmental factors such as growth factors, food, and toxins can reshape the methylome and eventually differentiate or transform a cell [
4,
5]. For example, knockdown of upstream estrogen receptors (ERs) increases methylation within ER target genes [
6]. Also, various concentrations of diets given to pregnant mice can lead to production of the methylation source
S-adenosylmethionine (SAM), altering methylation level at the promoter regions of fur color reporter genes and causing variegated fur color in the offspring [
7‐
9]. Furthermore, environmental toxins such as endocrine disrupters can change methylation states through different signaling pathways [
10,
11]. All of these examples demonstrate that the methylome is subject to further modifications.
Changes in the methylome are associated with cellular transformation [
2,
12‐
14]. Dramatic methylome changes can be initiated early during the production of germ line cells and even before implantation [
15,
16]. Particular changes of the methylome are associated with the specification of different cell lineages during development [
17,
18]. Deviating from a normal state, abnormal global hypomethylation or hypermethylation of tumor suppressor genes can induce cancer as revealed by genetic studies [
19,
20]. The accumulation of abnormal DNA methylation can be found after tumor formation, metastasis, and the development of drug resistance, although it’s not easy to form connections between particular changes in methylation and specific transformation events [
21].
Several changes in DNA methylation may affect cellular sensitivity to drug treatment. For example, increased DNA methylation within
BRCA1 promoter in ovarian cancer patients correlate with better platinum-based chemotherapy [
22]. By contrast, hypermethylation of
MLH1 is associated with increased cisplatin resistance in an ovarian cancer cell line [
23]. Also, hypermethylated
DAPK in colon and breast cancers correlates with drug resistance [
24,
25]. DAPK works through the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Hypermethylation within the
TRAIL gene correlates with drug resistance in lung cancer [
26], and the reversal of
TRAIL methylation by methylation inhibitor treatment restores sensitivity to drug treatment [
27‐
29]. These findings suggest that abnormal DNA methylation might affect cell death pathways and the development of drug resistance in cancer [
30,
31].
Identifying the methylation changes related to drug resistance might provide a diagnostic clue as to whether the development of drug resistance is methylation-dependent. Also, if changes in DNA methylation are sufficient to cause drug resistance in cancer, then the reversal of these changes might restore the sensitivity of cancer cells to drug treatment. In this report, we characterized the SiHa cancer cell-derived oxaliplatin-resistant cervical cancer cell line S3 [
32]. Treatment with a methylation inhibitor reversed drug resistance, indicating that the development of resistance is methylation-dependent [
33]. Differential methylation hybridization (DMH) microarray was performed to detect methylation changes associated with the development of drug resistance [
34,
35]. Previously, demethylation of these target loci restored the expression of the target genes and their sensitivities to different cancer drugs [
36‐
39]. Finally, we applied a two-component system to monitor DNA methylation of the identified target gene [
17,
40]
Casp8AP2 (NM_001137667) and found that increased methylation was associated with a drug-resistant phenotype. These findings suggest the possibility of identifying changes in methylation that are related to drug resistance in cancer.
Methods
Cell culture, isolation, and characterization
Human mesenchymal stem cells (MSCs) were isolated and cultured as described by Lee et al. [
41], and cell expansion was as described by Hsiao et al. [
17,
41]. MDA-MB-231, SiHa, and S3 cells were cultured with L-15, Minimum Essential Medium (MEM; Invitrogen), and MEM with 2 μg/ml oxaliplatin, respectively. For all cells, the medium was supplemented with 10 % fetal bovine serum (Invitrogen), 100 mg/ml penicillin/streptomycin (Invitrogen), and 2 mM
l-glutamine (Invitrogen).
5-Aza-2′-deoxycytidine (5-Aza) treatment
Cells were treated with 5 μM 5-aza or an equal volume of DMSO as a control for 5 consecutive days.
Cloning of the human Casp8AP2 promoter
Primers for the human
Casp8AP2 promoter are listed in Additional file
1: Table S1. Human MSC genomic DNA was used as a polymerase chain reaction (PCR) template. Purified PCR products were ligated into the
pyT&A cloning vector (Yeastern Biotech) according to the manufacturer’s protocol. Inserts were confirmed by restrictions and sequencing.
In vitro DNA methylation
PCR-amplified Casp8AP2 promoters (4 μg) were incubated with 20 units of CpG methyltransferase (New England BioLabs) at 37 °C for 4 h in the presence of 160 μM SAM to induce methylation.
Validation of in vitro DNA methylation
Methylated DNA showing resistance to methylation-sensitive restriction enzymes (
HpaII) was considered to indicate completed conversion (Additional file
1: Figure S1).
Transfection of methylated DNA
PCR products (0.4 μg/well, unmethylated as a control) were denatured at 95 °C and then transfected into 5 × 10
5 cells/well in a 6-well plate using DMRIE-C (Invitrogen) according to the manufacturer’s instructions. Cells were transfected three times, on day 1, 3, and 5 [
17,
42]. The transfection efficiency and the localization of the transfected DNA were tracked as in Additional file
1: Figure S2.
Bisulfite conversion
Genomic DNA (0.5 μg) was bisulfite-converted and purified as described by Yan et al. [
43].
Semi-quantitative real-time methylation-specific PCR (qMSP)
The qMSP was performed as described by Yan et al. [
43]. Bisulfite-converted genomic DNA was subject to real-time PCR with methylation-specific primers (Additional file
1: Table S1). A SYBR Green I PCR Kit (Toyobo) was used to conduct qMSP in an iQ5 PCR instrument (Bio-Rad). After reactions, analysis of melting temperature was performed to ensure that a specific amplicon was generated.
Col2A1 (NM_033150) was used for standard curve construction and as a loading control. Methylation percentage was calculated as: (mean of target gene)/(mean of
Col2A1). Fold change was calculated as: (targeted DNA methylation percentage)/(mock methylation percentage).
Differential methylation hybridization microarray, DMH
The DMH procedure was performed as described by Leu et al. [
44] using a human CpG microarray (Agilent). Treated and control genomic DNA (2 μg) was restricted into small fragments by
MseI and ligated with designated primers. Methylation-sensitive restriction enzymes (
BstUI and
HpaII) were used to discriminate between methylated and unmethylated DNAs, and DNAs was then amplified by PCR using adaptors as primers. PCR-amplified DNA from mock-treated S3 cells was labeled with Cy5 and from SiHa or 5-aza-treated S3 cells was labeled with Cy3 and then co-hybridized onto slides. After scanning, the ratio between Cy5 and Cy3 dyes was normalized by locally weighted scatterplot smoothing. Significant methylation differences were identified.
Semi-quantitative RT-PCR (qRT-PCR)
RNA isolation, first-strand cDNA synthesis, and detection of transcripts were carried out as previously described [
44]. Total RNA (2 μg) was reverse transcribed using SuperScript II reverse transcriptase (Invitrogen). qRT-PCR was performed using a SYBR Green I PCR Kit (Toyobo) in an iQ5 Real-Time instrument (Bio-Rad). A serial dilution of
GADPH-amplified (NM_002046) cDNA was used as a control to generate a standard curve, and
GAPDH from each sample was used as a loading control. The primers used are listed in Additional file
1: Table S1.
Cell survival assay
Cells (5 × 104) were plated into each well of a 96-well assay plate and allowed to attach. Cells were then treated with different concentrations of drugs and incubated at 37 °C overnight. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution (20 μl, 5 mg/ml; Sigma) was added to each well and incubated at 37 °C for 5 h. The reaction was terminated by adding 100 μl DMSO, and absorbance was measured at 595 nm.
Western blot analysis
Cells were harvested in RIPA buffer, and proteins were separated in 10 % polyacrylamide gel and trans-blotted onto a membrane. After blocking with skim milk, the membrane was hybridized with designated antibodies. After washing, secondary antibody conjugated with horseradish peroxidase was used to detect hybridization. Results were visualized by chemiluminescence. The film was then scanned and analyzed.
Immunostaining
Treated or control cells (5 × 104) were plated into 4-well chamber slides and allowed to attach. After washing and fixing in 2 % formaldehyde, cells were again washed and permeabilized by 0.5 % NP40 in phosphate-buffered saline (PBS). After another wash, horse serum in PBS (1:100) was used to block, and the slides were washed. Specific antibodies were used to stain the cells, and fluorescein-conjugated secondary antibodies were used to detect the staining. The slides were mounted, and cells were visualized using a fluorescent microscope.
Enzyme-linked immunosorbent assay (ELISA)
Green fluorescent protein (GFP) ELISA was performed using an ELISA Kit (Cell Biolabs) according to the manufacturer’s instructions. Starting from 2 × 104 cells per assay, the cells were harvested and lysed, and the collected proteins were quantified. Proteins (0.1 μg/ml per assay) were compared with the provided standard after binding to GFP antibody, secondary antibody, and substrate solution with vigorous washes between steps. After stopping the reaction, absorbance was measured at 595 nm.
Discussion
DNA methylation is an inheritable mark that could direct gene expression and cell fates [
45,
46]. Changes in DNA methylation often imply a detour in cell physiology and could serve as a way to further vary cellular transformation and clonal expansion [
47,
48]. Accumulating data correlates abnormal DNA methylation with tumorigenesis, metastasis, and the development of drug resistance [
47,
49]. Although genetic studies directly link abnormal DNA methylation to cellular transformation, how abnormal DNA methylation leads to the development of drug resistance is relatively unclear.
DNA methylation is a stable change, yet it is also reversible like other epigenetic modifications. Its stability makes methylation easy to detect, and its reversibility makes it a possible therapeutic target [
50,
51]. If methylation of a specific locus is sufficient to cause drug resistance, then detection of this modification might be used to monitor the development of drug resistance. Furthermore, if demethylation of a locus is closely related to the reversal of drug resistance, then it could be a candidate mechanism for restoring the sensitivity of cells to drug treatment. Therefore, we used DMH to identify several methylation changes occurring during the development of drug resistance. The loci that became hypermethylated and that showed a reversal of methylation after treatment with a demethylation agent could be primary targets [
52].
In the present study, by establishing a two-component system for monitoring targeted DNA methylation and quantifying the degree of methylation, we found that targeted Casp8AP2 methylation caused the development of cellular drug resistance in different lines of cells. This monitoring system could be further used to monitor environmentally induced changes in methylation state and to track targeted cells in their microenvironments.
Authors’ contributions
CCC, MYP, KDL, PYC, CCC, SHH and YWL carried out the molecular studies. KDL isolate the MSC. LTC and JYC isolated the S3 cells. CCC, SHS and YWL drafted and finished the manuscript. All authors read and approved the final manuscript.